This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bergerat, J.-P. Articles by Drewinko, B. Search for Related Content PubMed PubMed Citation Articles by Bergerat, J.-P. Articles by Drewinko, B.

Effects of cis-Dichlorodiammineplatinum(II) on Human Colon Carcinoma Cells in Vitro¹

Clinique des Maladies du Sang, Centre Hospitalier Universitaire de Strasbourg, 67000 France [J-P. B.], and Departments of Developmental Therapeutics [B. B.] and Laboratory Medicine [B. D.], The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030

The lethal effects of cis-dichlorodiammineplatinum(II) were investigated on an established human colon carcinoma cell line. cis-Dichlorodiammineplatinum(II) was one of the most efficient antineoplastic agents tested thus far on this human colon carcinoma cell line. Survival of exponentially growing cells exposed to increasing concentrations of the drug (both in medium or in Hanks' balanced salt solution) was of the threshold exponential type (D_q = 1.2 µg/ml, 1 hr; D₀ = 3.5 µg/ml, 1 hr). Stationary-phase cells were extremely sensitive to the drug, and the survival curve demonstrated a simple exponential pattern (D₀ = 3.9 µg/ml, 1 hr). Long-term exposure to low concentrations of cis-dichlorodiammineplatinum induced a high degree of killing, with only 0.5% of the cells surviving after incubation for 24 hr with 2 µg/ml. Cells were unable to recover from potentially lethal or sublethal damages induced by the drug.

¹ Supported by Grants CA 14528 and CA 16763 from the National Cancer Institute, NIH, USPHS.

² Supported by a grant from the Lilly International Fellowship Program, Indianapolis, Ind. 46206.

³ To whom requests for reprints should be addressed.

Received 5/ 1/78. Accepted 1/10/79.